Clearpoint Neuro (CLPT) Q4 2024 earnings summary

Executive summary

• Entered a new growth phase focused on scaling cell and gene therapy delivery, with over 60 biopharma partners and more than 100 activated centers globally.

• Unique platform integrates navigation, predictive modeling, delivery devices, and monitoring software, addressing a $500M current market and $10B potential.

• Achieved record 2024 revenue of $31.4 million, up 31% year-over-year, marking the tenth consecutive year of growth.

• Recent FDA approvals, including Kebilidi gene therapy co-labeled with SmartFlow Cannula, and seven clinical-stage partners with expedited FDA review.

• Activated 25 new global centers in 2024, tripling the historic activation rate and supporting expansion for cell and gene therapy treatments.

Financial highlights

• 2024 revenue was $31.4 million, up 31% from $24 million in 2023, with a 27% CAGR since 2018.

• Biologics and Drug Delivery revenue grew 27% to $17.3 million; Neurosurgery Navigation revenue rose 21% to $10.3 million; Capital Equipment and Software revenue increased 107% to $3.8 million.

• Gross margin improved to 61% in 2024 from 57% in 2023.

• Operational cash burn for 2024 was $9.0 million, a 35% reduction from 2023.

• Cash and cash equivalents at year-end: $20.1 million.

Outlook and guidance

• 2025 revenue guidance is $36–41 million, representing 15–31% growth, with the range driven by timing of preclinical GLP expansion.

• Targeting operational cash breakeven and 70%+ gross margins by expanding to 150+ global centers.

• Plans to launch new products, expand GLP preclinical services, and pursue additional regulatory approvals.

• Expect 15–20 new global site activations in 2025, building on 25 new activations in 2024.

• Anticipates meaningful revenue from royalty, milestone, and co-development agreements beyond product sales.